This article discusses the significance of the TLR6 gene in the complications of myeloma, a malignant tumor disease that develops from bone marrow plasma cells. Studies have shown that increased TLR6 gene expression in myeloma patients is associated with more severe complications and a worse disease prognosis. This may be due to increased inflammation in the body and increased activation of the immune system. Understanding the role of the TLR6 gene may help develop new approaches to the diagnosis, treatment and prevention of myeloma.

TLR6 gene, complications, prognosis

Bohnert V, Schäfer C, Müller-Tidow C, et al. Toll-like receptors in normal and malignant hematopoiesis. Curr Pharm Des. 2006;12(32):4219-4232. doi:10.2174/138161206779010392

Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93(9):3064-3073.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384. doi:10.1038/ni.1863

Vacca A, Ria R, Reale A, et al. TLR gene expression profile in human multiple myeloma cells: down-regulation of TLR3 expression. Cancer Immunol Immunother. 2006;55(7):910-920. doi:10.1007/s00262-005-0079-1

Botta C, Gulla A, Correale P, Tagliaferri P, Tassone P. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011;1(6):e27. doi:10.1038/bcj.2011.26